October 23, 2021

The World Stock Markets Tips & Targets, News, Views & Updates

The World Stock Markets Tips & Targets, News, Views & Updates

Covaxin for kids: SEC approves Bharat Biotech’s COVID vaccine for children from 2 to 18 yrs

Subject Expert Committee has approved Bharat Biotech’s covid vaccine ‘COVAXIN’ for children in the 2-18 age group. DCGI will now to take the final call. As part of the Phase II/III trial, the two-dose Covaxin was administered to 525 children 28 days apart. Bharat Biotech had received the drug regulators’ nod to conduct the children’s trial in May this year. Earlier the company had earlier indicated that if all goes well the vaccine for kids would be rolled out in October itself.

Share This :